Logo image of SNPX

SYNAPTOGENIX INC (SNPX) Stock Fundamental Analysis

NASDAQ:SNPX - Nasdaq - US87167T3005 - Common Stock - Currency: USD

7.85  +1.8 (+29.86%)

After market: 7.7001 -0.15 (-1.91%)

Fundamental Rating

2

Overall SNPX gets a fundamental rating of 2 out of 10. We evaluated SNPX against 553 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SNPX as it has an excellent financial health rating, but there are worries on the profitability. SNPX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SNPX has reported negative net income.
SNPX had a negative operating cash flow in the past year.
SNPX had negative earnings in each of the past 5 years.
In the past 5 years SNPX always reported negative operating cash flow.
SNPX Yearly Net Income VS EBIT VS OCF VS FCFSNPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of SNPX (-84.58%) is worse than 71.17% of its industry peers.
With a Return On Equity value of -201.09%, SNPX is not doing good in the industry: 67.26% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -84.58%
ROE -201.09%
ROIC N/A
ROA(3y)-45.16%
ROA(5y)-79.02%
ROE(3y)-90%
ROE(5y)-120.41%
ROIC(3y)N/A
ROIC(5y)N/A
SNPX Yearly ROA, ROE, ROICSNPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNPX Yearly Profit, Operating, Gross MarginsSNPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, SNPX has more shares outstanding
Compared to 5 years ago, SNPX has more shares outstanding
SNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SNPX Yearly Shares OutstandingSNPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
SNPX Yearly Total Debt VS Total AssetsSNPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -3.69, we must say that SNPX is in the distress zone and has some risk of bankruptcy.
SNPX has a Altman-Z score (-3.69) which is comparable to the rest of the industry.
There is no outstanding debt for SNPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.69
ROIC/WACCN/A
WACCN/A
SNPX Yearly LT Debt VS Equity VS FCFSNPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 72.70 indicates that SNPX has no problem at all paying its short term obligations.
SNPX's Current ratio of 72.70 is amongst the best of the industry. SNPX outperforms 99.82% of its industry peers.
A Quick Ratio of 72.70 indicates that SNPX has no problem at all paying its short term obligations.
The Quick ratio of SNPX (72.70) is better than 99.82% of its industry peers.
Industry RankSector Rank
Current Ratio 72.7
Quick Ratio 72.7
SNPX Yearly Current Assets VS Current LiabilitesSNPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.75% over the past year.
EPS 1Y (TTM)73.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%129.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SNPX will show a small growth in Earnings Per Share. The EPS will grow by 2.96% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.17%
EPS Next 2Y2.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNPX Yearly EPS VS EstimatesSNPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNPX Price Earnings VS Forward Price EarningsSNPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNPX Per share dataSNPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.96%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNAPTOGENIX INC

NASDAQ:SNPX (6/30/2025, 8:00:02 PM)

After market: 7.7001 -0.15 (-1.91%)

7.85

+1.8 (+29.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap10.91M
Analysts82.86
Price Target14.28 (81.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.82
Dividend Growth(5Y)N/A
DP-8.16%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.69
EV/EBITDA N/A
EPS(TTM)-9.81
EYN/A
EPS(NY)-7.17
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS0
BVpS4.64
TBVpS4.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.58%
ROE -201.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.16%
ROA(5y)-79.02%
ROE(3y)-90%
ROE(5y)-120.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 72.7
Quick Ratio 72.7
Altman-Z -3.69
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%129.54%
EPS Next Y-14.17%
EPS Next 2Y2.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.37%
OCF growth 3YN/A
OCF growth 5YN/A